Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer

British Journal of Cancer

Volumn 99, Issue 9, 2008, Pages 1395-1401

  Conroy, T ^a   Viret, F ^b   Francois E ^c   Seitz, J F ^d   Boige, V ^e   Ducreux, M ^e   Ychou, M ^f   Metges, J P ^g   Giovannini, M ^b   Yataghene, Y ^h   Peiffert, D ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d TIMONE HOSPITAL   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f CENTRE VAL D AURELLE   (France)

^g BREST UNIVERSITY HOSPITAL   (France)

^h SANOFI   (France)

Author keywords

Chemotherapy; FOLFOX; Oesophageal cancer; Oxaliplatin; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; ESOPHAGITIS; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SEPTIC SHOCK; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 55249095263     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604708     Document Type: Article

References (25)

1. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T (1997) Randomised phase II study of cisplatin and 5-fluorouracil (5FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33: 1216-1220
2. Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier AM, Guizard AV, Tretarre B, Launoy G, Colonna M, Danzon A, Molinie F, Troussard X, Bourdon-Raverdy N, Carli PM, Jaffré A, Bessaguet C, Sauleau E, Schvartz C, Arveux P, Maynadié M, Grosclaude P, Estève J, Faivre J (2007) Survival of cancer patients in France: a population-based study from the Association of the French Cancer Registries (FRANCIM). Eur J Cancer 43: 149-160
3. Bouvier AM, Binquet C, Gagnaire A, Jouve JL, Faivre J, Bedenne L (2006) Management and prognosis of esophageal cancers: has progress been made? Eur J Cancer 42: 228-233
4. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson Jr JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SI, Graham MV, Leichman LL (1999) Chemoradiotherapy of locally advanced esophageal cancer. Long term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 281: 1623-1627
5. Cunningham D, Rao S, Starling N, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman JAR, NCRI Upper GI Study Group (2006) Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. J Clin Oncol 24: 18S (part I): LBA4017
6. Declaration of Helsinki Laid down by the 18th World Medical Assembly (Helsinki, 1964) and amendments laid down by the 29th (Tokyo, 1975), the 35th (Venice, 1983), the 41st (Hong Kong, 1989) and the 48th (Somerset West, 1996) World Medical Assemblies
7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
8. Highley MS, Hill ME, Ziras N, Samandas N, Mason RC, Owen W, Dussek J, Barker S, Harper PG (1993) High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in the treatment of advanced gastric and oesophageal adenocarcinoma. Br J Cancer 67: 407-408
9. Johnson PW, Thompson PI, Seymour MT, Deasy NP, Thurainsingham RC, Slevin ML, Wrigley PF (1991) A less toxic regimen of 5FU and high dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer 64: 603-605
10. Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, Litwin A, Smith J, Nava E, Pendyala L, Smith P, Greco W, Berdzik J, Douglass H, Leichman L (2002) Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 20: 2844-2850
11. Louvet C, de Gramont A, Demuynck B, Nordlinger B, Maisani JE, Lagadec B, Delfau S, Varette C, Gonzalez-Canali G (1991) High dose folinic acid, 5FU bolus and continuous infusion in poor prognosis patients with advanced measurable gastric cancer. Ann Oncol 2: 229-230
12. Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, Vandenbulcke JM, Misset JL, Schwarzenberg L, Fourtillan JB (1986) Treatment of advanced colorectal and gastric adenocarcinomas with 5FU and high-dose folinic acid. J Clin Oncol 4: 685-695
13. Mauer AM, Kraut EH, Krauss SA, Ansari RH, Kasza K, Szeto L, Vokes EE, for the University of Chicago Phase II Network (2005) Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 16: 1320-1325
14. Maurel J, Cervantes A, Conill C, Salazar R, Martin-Richard M, Pera M, Manzano H, Chirivella I, Gallego R, Marfa X (2005) Phase I trial of oxaliplatin in combination with cisplatin, protracted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma. Int J Radiat Oncol Biol Phys 62: 91-96
15. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP (2002) INT 123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20: 1167-1174
16. National Cancer Institute (of the United States of America, NCI). Common Terminology Criteria for Adverse Events (CTC-AE), version 2.0. Available at: http://ctep.info.nih.gov/reporting/ctc.html
17. Note for Guidance from the European Agency for the Evaluation of Medicines (EMEA) (2003) Committee for Proprietary Medicinal Products (CPMP) adopted guideline. Note for Guidance on Evaluation of Anticancer Medicinal Products in Man-CPMP/EWP/205/95rev.2-corr, London, 24 July
18. O'Connor BM, Chadha MK, Pande A, Lombardo JC, Nwogu CE, Nava HR, Yang G, Javle MM (2007) Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma. Cancer J 13: 119-124
19. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108
20. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds) (2008) SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/ based on November 2007 SEER data submission, posted to the SEER web site, 2008.Accessed 18 April
21. Roca E, Pennella E, Sardi M, Carraro S, Barugel M, Milano C, Fiorini A, Giglio R, Gonzalez G, Kneitschel R, Aman E, Jarentchuk A, Blajman C, Nadal J, Santarelli MT, Navigante A (1996) Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer. Eur J Cancer 32A: 429-432
22. Rubin J, Gallagher JG, Schroeder G, Schutt AJ, Dalton RJ, Kugler JW, Morton RF, Mailliard JA, Burch PA (1996) Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 78: 1888-1891
23. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, Grosclaude P, Hédelin G, Matsuda T, Møller H, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D (2003) EUROCARE-3: survival of cancer patients diagnosed 1990-94. Results and commentary. Ann Oncol 14(Suppl 5): v61-v118
24. Stahl M, Wilke H, Meyer HJ, Preusser P, Berns T, Fink U, Achterrath W, Knipp H, Harstrick A, Berger M, Schmoll HJ (1994) 5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus. Eur J Cancer 30A: 325-328
25. van Meerten E, Esken FALM, van Gameren EC, Doorn L, van der Gaast A (2007) First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer 96: 1348-1352